Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation

被引：3

作者：

Eng, Kathleen ^{[1
]}

Zebardast, Nazlee ^{[2
]}

Boland, Michael, V ^{[2
,3
]}

Lo, Jui-en ^{[4
]}

Swaminathan, Swarup S. ^{[5
]}

Friedman, David S. ^{[2
,3
]}

Ma, Kevin sheng-kai ^{[6
]}

机构：

[1] Harvard Med Sch, Boston, MA USA

[2] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA USA

[3] Glaucoma Ctr Excellence, Boston, MA USA

[4] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Internal Med, Cleveland, OH USA

[5] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL USA

[6] Univ Penn, Ctr Global Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

AMERICAN JOURNAL OF OPHTHALMOLOGY | 2024年 / 271卷

关键词：

RECEPTOR AGONISTS; ANGLE-CLOSURE; RISK; EMPAGLIFLOZIN; DYSREGULATION; DISPERSION; OUTCOMES; DISEASE;

D O I：

10.1016/j.ajo.2024.10.029

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

to vascular remodeling effects have been demonstrated in patients with type 2 diabetes mellitus. It is unclear whether a similar benefit may be seen for glaucoma. The purpose of this study was to assess the effect of SGLT2i on the risk of glaucoma in patients with type 2 diabetes. center dot DESIGN: Target trial emulation using observational data from multiple healthcare organizations. center dot METHODS: This population-based cohort study included adults with type 2 diabetes in the United States who newly initiated treatment with SGLT2i, dipeptidyl peptidase 4 inhibitors (DPP4i), or glucagon-like peptide1 receptor agonists (GLP1RA) between 2013 and 2023. Propensity score matching was conducted to control for sociodemographic characteristics comorbidities, and concomitant use of medications. The exposure considered was treatment with SGLT2i for type 2 diabetes, and the outcomes were new-onset glaucoma and its subtypes after initiation of antidiabetic treatments. Subgroup analyses were performed to evaluate the effect of individual SGLT2i on incident glaucoma. center dot RESULTS: After propensity score matching, 722,446 patients were included in the SGLT2i arm and the DPP4i arm, respectively. Patients on SGLT2i, compared with

引用

页码：286 / 298

页数：13

共 44 条

[1]

Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J., Epidemiology of type 2 diabetes - global burden of disease and forecasted trends, J Epidemiol Glob Health, 10, 1, pp. 107-111, (2020)

[2]

Cha A.E., Villarroel M.A., Vahratian A., Eye disorders and vision loss among U.S. adults aged 45 and over with diagnosed diabetes, 2016-2017, NCHS Data Brief, 344, pp. 1-8, (2019)

[3]

Zhao Y.X., Chen X.W., Diabetes and risk of glaucoma: systematic review and a meta-analysis of prospective cohort studies, Int J Ophthalmol, 10, 9, pp. 1430-1435, (2017)

[4]

Zhao D., Cho J., Kim M.H., Friedman D.S., Guallar E., Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis, Ophthalmology, 122, 1, pp. 72-78, (2015)

[5]

Dziuba J., Alperin P., Racketa J., Et al., Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes, Diabetes Obes Metab, 16, 7, pp. 628-635, (2014)

[6]

Ott C., Jumar A., Striepe K., Et al., A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation, Cardiovasc Diabetol, 16, 1, (2017)

[7]

Anker S.D., Butler J., Filippatos G., Et al., Empagliflozin in heart failure with a preserved ejection fraction, N Engl J Med, 385, 16, pp. 1451-1461, (2021)

[8]

Perkovic V., Jardine M.J., Neal B., Et al., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med, 380, 24, pp. 2295-2306, (2019)

[9]

Wanner C., Inzucchi S.E., Lachin J.M., Et al., Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 4, pp. 323-334, (2016)

[10]

Zinman B., Wanner C., Lachin J.M., Et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 22, pp. 2117-2128, (2015)

← 1 2 3 4 5 →